The application of targeted protein degradation technologies to G protein‐coupled receptors
British Journal of Pharmacology · 2024-07 · 181 (14) · 2351-2358
DOI: 10.1111/bph.16079 ↗At a glance
Übersichtsarbeit in British Journal of Pharmacology, published online on 2023-04-20. Written by Alastair C Keen and 2 co-authors. Institution: Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, 399 Royal Parade, Parkville, 3052, Victoria, Australia. Major MEDLINE topics: Receptors, G-Protein-Coupled, Proteolysis. Cited 18 times so far (Crossref); 46 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Sylvia and Charles Viertel Charitable Foundation, Research England.
Abstract (original language)
The ubiquitin‐proteasome system is one of the major pathways for the degradation of cellular proteins. In recent years, methods have been developed to exploit the ubiquitin‐proteasome system to artificially degrade target proteins. Targeted protein degraders are extremely useful as biological tools for discovery research. They have also been developed as novel therapeutics with several targeted protein degraders currently in clinical trials. However, almost all targeted protein degrader technologies have been developed for cytosolic proteins. The G protein‐coupled receptor (GPCR) superfamily is one of the most important classes of drug targets, yet only limited examples of GPCR degradation exist. Here, we review these examples and provide a perspective on the different strategies that have been used to apply targeted protein degradation to GPCRs. We also discuss whether alternative approaches that have been used to degrade other integral membrane proteins could be applied to the degradation of GPCRs. LINKED ARTICLES This article is part of a themed issue Therapeutic Targeting of G Protein‐Coupled Receptors: hot topics from the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists 2021 Virtual Annual Scientific Meeting. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v181.14/issuetoc
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, 399 Royal Parade, Parkville, 3052, Victoria, Australia.
- Medicinal Chemistry Theme, Monash Institute of Pharmaceutical Sciences, Monash University, 399 Royal Parade, Parkville, 3052, Victoria, Australia.
- Newcastle University Centre for Cancer, Chemistry - School of Natural and Environmental Sciences, Newcastle University, Bedson Building, Newcastle Upon Tyne, NE1 7RU, UK.
ORCID profiles: Alastair C Keen, Manuela Jörg, Michelle L Halls
Funding
- Sylvia and Charles Viertel Charitable Foundation
- Research England
Cite
APA
Keen, A. C., Jörg, M., & Halls, M. L. (2024). The application of targeted protein degradation technologies to G protein‐coupled receptors. British Journal of Pharmacology, 181(14), 2351-2358. https://doi.org/10.1111/bph.16079
Vancouver
Keen AC, Jörg M, Halls ML. The application of targeted protein degradation technologies to G protein‐coupled receptors. British Journal of Pharmacology. 2024;181(14):2351-2358. doi:10.1111/bph.16079
BibTeX
@article{Keen2024,
author = {Keen, Alastair C and Jörg, Manuela and Halls, Michelle L},
title = {The application of targeted protein degradation technologies to G protein‐coupled receptors},
journal = {British Journal of Pharmacology},
year = {2024},
volume = {181},
number = {14},
pages = {2351--2358},
doi = {10.1111/bph.16079}
}
EUVIMED